Antibe Therapeutics Inc(Pre-Merger) ATBPF

RE:RE:2 Questions

[PoorOpinion]

Jefferam1 wrote: 1. - I agree
2. - I believe I have mentioned this back in Sep/Oct. Stating people who are not already in would be in their best interest to wait till Dec or early Jan (I might of just said Dec expecting results sooner) because this very reason. The longer people wait to get in while having share price not go up significantly de-risks the investment. The trick will be timing. By now they must be on the last half of the trial. This is very encouraging that we have no news. However the one significant catalyst we all need is for positive results. Proof that ATB-346 prevents GI damage will be significant to ATE. Even though it is de-risking itself now, that's only a marginal effect compared to positive results.
Having a drug that is safe but not effective won't do us any good (which obviously we all know this).
So if we think for a sec that it doubled in value without any positive news, how many times will it increase with the positive news? 3x? 5x? 10x?
My best guess 3x because I'm trying to be conservative, but my hopes are for more.

Certainly the two questions are important but as Jeff says the really big news is the GI tract protection. I guess most here have read the paper about the rat model for GI protection. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848928/ I read it again recently, I forgot just how good a piece of science I thought it was. They basically slice and dice the problem so many different ways with many different experimental approaches. They covered many of the alternative possible reasons why the data looks the way it does. It's hard to find a flaw or to question the conclusion that the drug really works (in rats). That was my opinion anyway, anybody see any weaknesses? There are a few unanswered questions in my mind but general its a great piece of science. If the human data comes anywhere near the rat data then this is a real step forward and best in class drug.